COVID-19 Survivors Overestimate Lingering Taste Impairment
TUESDAY, Jan. 11, 2022 (HealthDay News) -- More than half of patients with self-reported long-term altered taste perception following COVID-19 actually have normal gustatory function when evaluated with validated psychophysical tests, according to a research letter published online Jan. 6 in JAMA Otolaryngology-Head & Neck Surgery.
Paolo Boscolo-Rizzo, M.D., from the University of Trieste in Italy, and colleagues examined whether psychophysical tests confirm a self-reported alteration of taste among patients self-reporting a persistent distorted perception of basic tastes three or more months after acute COVID-19. The analysis included 105 adult patients with psychophysical evaluation performed a median of 226 days after illness onset.
The researchers found that 98.1 percent had mildly symptomatic COVID-19 with no evidence of pneumonia. Almost all patients (94.3 percent) self-reported an associated olfactory impairment. A Taste Strips Score showed the prevalence of hypogeusia was 41.9 percent and dropped to 28.6 percent when adjusting for age. Only three patients (2.9 percent) had hypogeusia and were normosmic. With an increasing Threshold, Discrimination, and Identification score, the prevalence of normogeusic patients increased. Among 61 patients who were normogeusic, the majority (83.6 percent) had a TDI score <30.75 and 26.2 percent had a retronasal score <12. Only 16.4 percent had both normal orthonasal and retronasal olfactory function.
"This psychophysical study uncovers overestimation of self-reported taste impairment and supports the use of validated psychophysical tests to estimate the burden of chemosensory dysfunction in people with long-term COVID-19," the authors write.
Related Posts
Model Targeting Appetitive Traits Aids Weight Loss
WEDNESDAY, May 25, 2022 (HealthDay News) -- A novel intervention targeting...
PLCOm2012 Models Have High Sensitivity for Lung Cancer
TUESDAY, Oct. 10, 2023 (HealthDay News) -- Two versions of the PLCOm2012...
Harnessing a Virus to Fight a Killer Brain Tumor in Kids
THURSDAY, June 30, 2022 (HealthDay News) -- A therapy that uses a virus to kill...
Gefapixant Leads to Modest Improvements in Cough
MONDAY, Sept. 11, 2023 (HealthDay News) -- For adults with refractory or...